p.81 抽出テキスト

Kusumoto et al 2018 Bradycardia Clinical Practice Guidelines

August 20, 2019 Circulation. 2019;140:e382–e482. DOI: 10.1161/CIR.0000000000000628 e462

CLINICAL STATEMENTS AND GUIDELINES 5.3.2.4 Aminophylline or Theophylline for Bradycardia Attributable to SND

S5.3.2.4-1.	 Rothman SA, Jeevanandam V, Seeber CP, et al. Electrophysiologic effects of intravenous aminophylline in heart transplant recipients with sinus node dysfunction. J Heart Lung Transplant. 1995;14:429–35. S5.3.2.4-2.	 Redmond JM, Zehr KJ, Gillinov MA, et al. Use of theophylline for treatment of prolonged sinus node dysfunction in human orthotopic heart transplantation. J Heart Lung Transplant. 1993;12:133–8; discussion 8–9. S5.3.2.4-3.	 Heinz G, Kratochwill C, Buxbaum P, et al. Immediate normalization of profound sinus node dysfunction by aminophylline after cardiac transplantation. Am J Cardiol. 1993;71:346–9. S5.3.2.4-4.	 Bertolet BD, Eagle DA, Conti JB, et al. Bradycardia after heart transplantation: reversal with theophylline. J Am Coll Cardiol. 1996;28:396–9. S5.3.2.4-5.	 Schulz-Stubner S. The use of small-dose theophylline for the treatment of bradycardia in patients with spinal cord injury. Anesth Analg. 2005;101:1809–11. S5.3.2.4-6.	 Sadaka F, Naydenov SK, Ponzillo JJ. Theophylline for bradycardia secondary to cervical spinal cord injury. Neurocrit Care. 2010;13:389–92. S5.3.2.4-7.	 Pasnoori VR, Leesar MA. Use of aminophylline in the treatment of severe symptomatic bradycardia resistant to atropine. Cardiol Rev. 2004;12:65–8. S5.3.2.4-8.	 Lou Q, Glukhov AV, Hansen B, et al. Tachy-brady arrhythmias: the critical role of adenosine-induced sinoatrial conduction block in post-tachycardia pauses. Heart Rhythm. 2013;10:110–8. S5.3.2.4-9.	 Ogilvie RI. Clinical pharmacokinetics of theophylline. Clin Pharmacokinet. 1978;3:267–93. S5.3.2.4-10.	 Hurley KF, Magee K, Green R. Aminophylline for bradyasystolic cardiac arrest in adults. Cochrane Database Syst Rev. 2015:CD006781. S5.3.2.4-11.	 Hamon D, Taleski J, Vaseghi M, et al. Arrhythmias in the heart transplant patient. Arrhythm Electrophysiol Rev. 2014;3:149–55. S5.3.2.4-12.	 Melton IC, Gilligan DM, Wood MA, et al. Optimal cardiac pacing after heart transplantation. Pacing Clin Electrophysiol. 1999;22:1510–27. S5.3.2.4-13.	 Woo GW, Schofield RS, Pauly DF, et al. Incidence, predictors, and outcomes of cardiac pacing after cardiac transplantation: an 11-year retrospective analysis. Transplantation. 2008;85:1216–8. S5.3.2.4-14.	 Manogue M, Hirsh DS, Lloyd M. Cardiac electrophysiology of patients with spinal cord injury. Heart Rhythm. 2017;14:920–7. S5.3.2.4-15.	 Lehmann KG, Lane JG, Piepmeier JM, et al. Cardiovascular abnormalities accompanying acute spinal cord injury in humans: incidence, time course and severity. J Am Coll Cardiol. 1987;10:46–52. S5.3.2.4-16.	 Bernheim A, Fatio R, Kiowski W, et al. Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon. Transplantation. 2004;77:1181–5. S5.3.2.4-17.	 Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S444–64. S5.3.2.4-18.	 Epstein AE, Hirschowitz BI, Kirklin JK, et al. Evidence for a central site of action to explain the negative chronotropic effect of atropine: studies on the human transplanted heart. J Am Coll Cardiol. 1990;15:1610–7. S5.3.2.4-19.	 Weant KA, Kilpatrick M, Jaikumar S. Aminophylline for the treatment of symptomatic bradycardia and asystole secondary to cervical spine injury. Neurocrit Care. 2007;7:250–2. S5.3.2.4-20.	 Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation. 1999;41:47–55. S5.3.2.4-21.	 Scheinman MM, Thorburn D, Abbott JA. Use of atropine in patients with acute myocardial infarction and sinus bradycardia. Circulation. 1975;52:627–33. S5.3.2.4-22.	 Swart G, Brady WJ Jr, DeBehnke DJ, et al. Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg Med. 1999;17:647–52. S5.3.2.4-23.	 Warren JV, Lewis RP. Beneficial effects of atropine in the pre-

hospital phase of coronary care. Am J Cardiol. 1976;37:68–72. S5.3.2.4-24.	 Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular

block in acute inferior myocardial infarction. J Am Coll Cardiol. 1984;4:35–8. S5.3.2.4-25.	 Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and effectiveness of prehospital pacing versus conventional treatment: ‘PrePACE.’ Resuscitation. 2008;76:341–9. S5.3.2.4-26.	 Mandel WJ, Hayakawa H, Allen HN, et al. Assessment of sinus node function in patients with the sick sinus syndrome. Circulation. 1972;46:761–9. S5.3.2.4-27.	 Ogawa H, Inoue T, Miwa S, et al. Heart rate responses to autonomic drugs in sick sinus syndrome–correlation with syncope and electrophysiologic data. Jpn Circ J. 1991;55:15–23. S5.3.2.4-28.	 Strauss HC, Bigger JT, Saroff AL, et al. Electrophysiologic evaluation of sinus node function in patients with sinus node dysfunction. Circulation. 1976;53:763–76. S5.3.2.4-29.	 Gee SW, Karsies TJ. Listeria meningitis-associated bradyarrhythmia treated with isoproterenol. Am J Emerg Med. 2015;33:306.e1–2. S5.3.2.4-30.	 Herman SC, Zhou J. Isoproterenol infusion for treatment of refractory symptomatic bradycardia in parturients with congenital complete heart block. Int J Obstet Anesth. 2011;20:361–3. author reply 3. S5.3.2.4-31.	 Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency department. Resuscitation. 2007;73:96–102. S5.3.2.4-32.	 Chihrin SM, Mohamed U, Yee R, et al. Utility of isoproterenol in unmasking latent escape rhythm in pacemaker dependent patients undergoing pacemaker replacement. Am J Cardiol. 2008;101:631–3. S5.3.2.4-33.	 Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support. 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S444–64. S5.3.2.4-34.	 Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol. 1994;13:161–6. S5.3.2.4-35.	 Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med. 1993;22:196–200. S5.3.2.4-36.	 St-Onge M, Dube PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol (Phila). 2014;52:926–44. S5.3.2.4-37.	 Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41:595–602. S5.3.2.4-38.	 Love JN, Sachdeva DK, Bessman ES, et al. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. Chest. 1998;114:323–6. S5.3.2.4-39.	 Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol (Phila). 2011;49:277–83. S5.3.2.4-40.	 Greene SL, Gawarammana I, Wood DM, et al. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007;33:2019–24. S5.3.2.4-41.	 Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81:1744–52. S5.3.2.4-42.	 Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52:824–36. S5.3.2.4-43.	 Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17:590–8. S5.3.2.4-44.	 Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36:3014–8. S5.3.2.4-45.	 Lapostolle F, Borron SW, Verdier C, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008;34:1448–53. S5.3.2.4-46.	 Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threaten-

ing digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. N Engl J Med. 1982;307:1357–62.

Downloaded from http://ahajournals.org by on October 7, 2026